Second, our included cohorts might not be representative of current populations in terms of T2D management using SGLT2 inhibitors or GLP1 receptor agonists which have shown to reduce CVD events in clinical trials.27 The gene discussed is GLP1R; the disease is type 2 diabetes mellitus.